Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in ...

With sales of $91 million, Uplizna came up $20 million short of the consensus projection. Meanwhile, Krystexxa’s haul of $236 million was $57 million shy of expectations, and Tepezza’s $381 ...

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.4% ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

Turning to rare disease. Our four key growth drivers: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS, are all early in their life cycles and well positioned for long-term growth. UPLIZNA is a ...

Turning to rare disease. UPLIZNA recently launched as the first FDA-approved therapy for IgG4-related disease, and we're now on track for a December 14th PDUFA date in generalized myasthenia gravis.